On December 7, 2021, Daré announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.
Similarly Is DARE FDA approved? DARE-BV1 (clindamycin phosphate) was approved today by the US Food and Drug Administration (FDA) to treat bacterial vaginosis. DARE-BV1 was developed by Daré Bioscience, Inc., a clinical-stage biopharmaceutical company that develops and advances women’s health products.
Will DARE stock go up? On average, Wall Street analysts predict that DARE BIOSCIENCE’s share price could reach $8.50 by Apr 1, 2023. The average DARE BIOSCIENCE stock price prediction forecasts a potential upside of 502.84% from the current DARE share price of $1.41.
Additionally, How much is target DARE?
Stock Price Targets
| High | $17.00 |
|---|---|
| Median | $6.00 |
| Low | $3.00 |
| Average | $7.20 |
| Current Price | $1.4100 |
Can I dare Bioscience bacterial vaginosis?
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
What is DARE Bioscience press release? Press Releases
- Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022. 03-24-2022.
- Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference. 03-22-2022.
- Daré Bioscience to Participate in Upcoming Conferences. 03-02-2022.
What is the stock of DARE Pharma? (DARE) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 1.4900 |
|---|---|
| 52 Week Range | 1.2000 – 2.5100 |
| Volume | 6,361,573 |
| Avg. Volume | 2,143,816 |
What is Xaciato? XACIATO is a lincosamide antibacterial indicated for the. treatment of bacterial vaginosis in female patients 12 years of. age and older. (
Who is the CEO of DARE Bioscience?
Sabrina Martucci Johnson. Ms. Johnson founded Daré Bioscience Operations in 2015 and has served as President, CEO and a member of the Board of Directors since its inception and following its business combination with Cerulean Pharma in July 2017, when the Company was renamed Daré Bioscience.
What rating is dare Bioscience? The consensus rating score for Daré Bioscience is 3.00 while the average consensus rating score for medical companies is 2.73.
What is the stock of Dare Pharma?
(DARE) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 1.4900 |
|---|---|
| 52 Week Range | 1.2000 – 2.5100 |
| Volume | 6,361,573 |
| Avg. Volume | 2,143,816 |
What happens on Pdufa date? In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application.
How much does a stock go up after FDA approval?
Result: You can see the stock experienced a slight increase after the FDA approval start date in early May. Subsequently the stock continued a steady increase of 17% between the start and end of the approval process. What is the Value of These Dates to Investors and Traders?
What happens to stock price after FDA approval?
Answering the question, « Does a Drug Approval Mean a Higher Stock Price? » is fairly straight forward, but there are some caveats that investors need to be aware of. The simple answer is yes, in most cases a new drug approval can lead to a higher share price for the company on the receiving end of that approval.
What does Gdufa stand for? On August 18, 2017, the President signed into law the Food and Drug Administration Reauthorization Act (FDARA), which includes the reauthorization of the Generic Drug User Fee Amendments (GDUFA) through September 2022.
